← Leaderboards
Suzanne Lentzsch
Columbia University Health Sciences
$3,325,846
Attributed
$5,578,928
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,178,928 · 4
FDA$400,000 · 1
By mechanism
R01$4,435,710 · 3
K12$627,956 · 1
R21$515,262 · 1
Top collaborators
- Jing Fu5 shared
- Markus Y Mapara5 shared
- Raymond Luke Comenzo2 shared
- Dawn Hershman2 shared
- Lisa A. Kachnic2 shared
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Jing Fu$788,407
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsMalignant NeoplasmsCellsMultiple MyelomaMediatingBone ResorptionBone DiseasesPlayLyticLesionIn VivoPathway InteractionsCollagenase 3OsteoclastsIntegral Membrane ProteinIn VitroBonePathologicEnvironmentGrantKnock-DownMononuclearMatrix MetalloproteinasesDisease Remission
Grant awards (16)
CUIMC Calabresi Clinical Oncology Career Development Program$573,987
K12 · FY2025 · CA
Binding of MMP13 to Immune Checkpoint Receptor PD-1H links Bone Disease with Immune Suppression in Multiple Myeloma$478,447
R01 · FY2025 · CA · contact PI
Binding of MMP13 to Immune Checkpoint Receptor PD-1H links Bone Disease with Immune Suppression in Multiple Myeloma$454,526
R01 · FY2024 · CA · contact PI
CUIMC Calabresi Clinical Oncology Career Development Program$53,969
K12 · FY2024 · CA
Binding of MMP13 to Immune Checkpoint Receptor PD-1H links Bone Disease with Immune Suppression in Multiple Myeloma$468,878
R01 · FY2023 · CA · contact PI
Binding of MMP13 to Immune Checkpoint Receptor PD-1H links Bone Disease with Immune Suppression in Multiple Myeloma$469,148
R01 · FY2022 · CA · contact PI
Binding of MMP13 to Immune Checkpoint Receptor PD-1H links Bone Disease with Immune Suppression in Multiple Myeloma$494,221
R01 · FY2021 · CA · contact PI
Screening to Improve Survival in AL Amyloidosis$269,446
R21 · FY2021 · AG
Screening to Improve Survival in AL Amyloidosis$245,816
R21 · FY2020 · AG
The Role of MMP13 in Multiple Myeloma Bone Disease$331,098
R01 · FY2018 · CA · contact PI
The Role of MMP13 in Multiple Myeloma Bone Disease$331,098
R01 · FY2017 · CA · contact PI
The Role of MMP13 in Multiple Myeloma Bone Disease$331,098
R01 · FY2016 · CA · contact PI
Phase 1a/1b Study of 11-1F4 mAb for the Treatment of AL Amyloidosis$200,000
R01 · FY2016 · FD · contact PI
The Role of MMP13 in Multiple Myeloma Bone Disease$331,098
R01 · FY2015 · CA · contact PI
Phase 1a/1b Study of 11-1F4 mAb for the Treatment of AL Amyloidosis$200,000
R01 · FY2015 · FD · contact PI
The Role of MMP13 in Multiple Myeloma Bone Disease$346,098
R01 · FY2014 · CA · contact PI